Table 3 Incidence of clinically relevant toxicities

From: A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours

 

Dose (mg m−2) (n)

 

Grade

 

300 (3)

500 (3)

600 (3)

700 (6)

800 (3)

900 (4)

1000 (3)

1200 (6)

Toxicity

1/2

3/4

1/2

3/4

1/2

3/4

1/2

3/4

1/2

3/4

1/2

3/4

1/2

3/4

1/2

3/4

Hematologic

                

 Erythropenia

1

0

1

0

3

0

4

0

2

0

2

0

2

0

5

0

 Hematocrit decreased

1

0

1

0

3

0

4

0

3

0

2

0

2

0

5

0

 Haemoglobin decreased

2

0

2

0

2

0

3

0

2

0

1

1

2

0

4

1

 Leucopenia

1

0

3

0

2

1

3

1

1

1

1

1

1

0

5

1

 Lymphopenia

0

0

2

1

0

1

3

0

1

0

1

1

3

0

4

1

 Neutropenia

1

0

1

2

1

2

3

2

0

2

1

1

2

0

2

1

 Thrombocytopenia

0

0

2

0

1

0

2

0

2

0

2

0

1

0

2

0

Nonhematologic

                

 ALT elevation

0

0

2

0

2

0

2

3

3

0

1

1

1

0

5

0

 AST elevation

0

0

3

0

2

0

4

1

3

0

3

0

2

0

5

0

 Blood bilirubin increased

0

0

1

0

0

0

2

0

0

0

0

0

0

0

1

0

 LDH elevation

0

0

3

0

3

0

5

0

3

0

2

0

1

0

4

0

 Alopecia

0

0

0

0

2

0

2

0

1

0

2

0

0

0

0

0

 Anorexia

0

0

1

0

3

0

5

0

3

0

0

1

3

0

4

0

 Constipation

1

0

1

0

0

0

1

0

0

0

0

0

2

0

1

0

 Diarrhoea

0

0

2

0

1

0

1

0

1

0

1

0

1

0

2

0

 Fatigue

1

0

2

0

2

0

2

0

3

0

1

0

2

0

3

0

 Infection

0

0

0

0

0

0

2

0

0

0

0

0

0

0

0

1

 Nausea

2

0

3

0

3

0

5

0

3

0

2

0

2

0

5

0

 Malaise

0

0

0

0

1

0

0

1

0

0

0

0

0

0

0

0

 Pruritus

0

0

0

0

2

0

2

0

1

0

0

0

1

0

2

0

 Rash

3

0

2

0

3

0

5

0

2

0

4

0

3

0

5

1

 Vomiting

2

0

3

0

2

0

3

0

1

0

1

0

1

0

0

0

  1. ALT=alanine transaminase; AST=aspartate transaminase; LDH=lactate dehydrogenase.
Back to article page